Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01912404 · ClinicalTrials.gov registry record · Phase 2
Study of IDN-6556 in Patients With Severe Alcoholic Hepatitis and Contraindications to Steroid Therapy
A Phase 2 study, sponsored by Conatus Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT01912404 is a Phase 2 study that was terminated before completion, run by Conatus Pharmaceuticals. The registered enrollment target is 5 participants.
The verdict
NCT01912404, a Phase 2 study, was terminated before completion, sponsored by Conatus Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
The main purpose of the study is to test if taking a study drug called emricasan (also known as IDN-6556 and PF-03491390) will affect overall patient survival after one month of treatment.
Interventions
- DRUG Placebo
- DRUG IDN-6556
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2013-07 |
| Est. Completion | 2015-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01912404
The ClinicalTrials.gov registry entry for NCT01912404 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Conatus Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01912404 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01912404 about?
NCT01912404 is a clinical study titled "Study of IDN-6556 in Patients With Severe Alcoholic Hepatitis and Contraindications to Steroid Therapy". The main purpose of the study is to test if taking a study drug called emricasan (also known as IDN-6556 and PF-03491390) will affect overall patient survival after one month of treatment.
What is the current status of trial NCT01912404?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2013-07. Estimated completion is 2015-08.
What interventions are being tested in trial NCT01912404?
The interventions under investigation include: Placebo (DRUG), IDN-6556 (DRUG).
Who is sponsoring clinical trial NCT01912404?
This trial is sponsored by Conatus Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.